Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:58 PM
Ignite Modification Date:
2025-12-24 @ 12:58 PM
NCT ID:
NCT02350361
Eligibility Criteria:
Inclusion Criteria:
* Patients with pathologic confirmation of NSCLC with tissue diagnosis or cytologic diagnosis, whose NSCLCs are locally advanced or metastatic Stage III-B / IV adenocarcinoma, and are inoperable and incurable with radiotherapy.
* Life expectancy of at least three (3) months after the start of administration of the investigational drug.
* Eastern Cooperative Oncology Group (ECOG) performance Score 0 to 2.
* Patients with at least one tumor lesion that can accurately be measured by CT or MRI in at least one dimension with longest diameter to be recorded as no less than double the slice thickness and \>=10 mm.
* Patient received at least 6 months EGFR-TKI and show tumor progress
* Adequate hematologic hepatic and renal functions based on the normal conditions of chemotherapy
* Patient signed consent form and adherence and geographic location are liable to follow up
Exclusion Criteria:
* CNS metastasis
* Active infection
* Bleeding tendency or blood coagulation dysfunction
* History of neurological or psychiatric disorders, including epilepsy, or dementia
* Pregnancy or breast-feeding women
* Organ transplant long-term use of immunosuppressive drugs
* Arrhythmia need anti-arrhythmic treatment or other risk of heart disease
* Use other targeted drugs during the research
* Other conditions may not allowed to join in this study according to the researcher's judgment
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT02350361
Study Brief:
Protocol Section:
NCT02350361